Abstract:

Objective   To explore the spectrum of mineral and bone disorders among hemodialysis patients.  Methods   Ninety-one maintenance hemodialysis patients from our dialysis center were included in the study. Markers of mineral and bone disorders, including plasma phosphorus (P), calcium (Ca) and intact parathyroid hormone (iPTH) were measured among ninety-one patients receiving hemodialysis.  The controlling rates of those markers were compared with the results in the Dialysis Outcomes and Practice Study (DOPPS) 4 study. Factors associated with hyperphosphatemia were examined.  Results   According to the Kidney Disease Outcomes Quality Initiative target for plasma P, Ca and iPTH levels, the percentages of patients with controlled Ca (58.2% vs 56.0%), P (49.5% vs 54.5%) and iPTH (34.1% vs 32.1%) were not statistically different compared with those in the DOPPS 4 study. The percentage of hemodialysis patients with serum phosphorus level above 5.5mg/dL was 42.9%. Age (odd ratio 0.96, 95% confidence interval: 0.94-0.99) and pre-albumin (odd ratio 1.01, 95% confidence interval: 1.0-1.02) were independently associated with hyperphosphatemia.  Conclusion    Status of mineral and bone disorders is relatively optimal among our hemodialysis patients compared with those in the DOPPS 4 study. Hyperphosphatemia is prominent and needs further attention.

Key words: End stage renal disease; Mineral; Bone diseases, metabolic; Epidemiology； Hemodialysis